Vestronidase alfa (brand name Mepsevii) is a medicine used to treat the rare genetic disorder Mucopolysaccharidosis type VII (MPS VII, also known as Sly syndrome). It is a recombinant form of the human lysosomal enzyme beta-glucuronidase. Vestronidase alfa is administered by intravenous (IV) infusion every two weeks. It works by replacing the missing or low levels of enzyme beta-glucuronidase that occur in patients with MPS VII. Vestronidase alfa helps break down certain complex carbohydrates and helps reduce the amount of undigested material that accumulates in cells and tissues. This helps to improve symptoms, slow down the progression of the disease, and improve overall quality of life.
Vestronidase alfa, sold under the brand name Mepsevii, is a medication used to treat Sly syndrome [1]. Here's a breakdown of its key aspects:
What it is:
- A recombinant form of the human enzyme beta-glucuronidase [1, 2].
- Produced using recombinant DNA technology [2].
What it's used for:
- Treats Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome [1].
- MPS VII is an inherited, rare genetic disorder [2].
How it works:
- In MPS VII, the body lacks the enzyme beta-glucuronidase, leading to a buildup of harmful substances in cells [2].
- Vestronidase alfa acts as an artificial replacement for the missing enzyme [2].
- It helps break down the accumulated substances, potentially improving symptoms of MPS VII [2, 3].
How it's given:
- Administered through intravenous (IV) infusion every two weeks [1].
Potential side effects:
- Infusion site reactions [8].
- Diarrhea [8].
- Rash [8].
- In rare cases, severe allergic reactions (anaphylaxis) [8].
Important things to know:
- Vestronidase alfa is a first-in-class medication for MPS VII [4].
- It's considered a life-long treatment [3].
- If you have any questions or concerns about Vestronidase alfa, consult a healthcare professional.
Additional Resources:
- You can find more detailed information about Vestronidase alfa on Wikipedia: en.wikipedia.org/wiki/Vestronidase_alfa.